Genome-wide analyses report that GHK modulates the expression of more than 4,000 human genes, corresponding to about 32 percent of the genome (Pickart & Margolina, IJMS 2018)
Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
This injection also has positive effects on lambs
Think of these as common patterns your provider may follow, not rigid rules
While it has been in research for over 20 years, it has recently gained a second life thanks to the massive public interest in peptide therapy and the rise of GLP-1 medications.